Phase 1 trial evaluating MBX 4291 in healthy overweight volunteers
Latest Information Update: 23 Jun 2025
At a glance
- Drugs MBX 4291 (Primary)
- Indications Obesity
- Focus Adverse reactions
Most Recent Events
- 23 Jun 2025 New trial record
- 16 Jun 2025 According to a MBX Biosciences media release, Company is planning to initiate this study in the third quarter of 2025.